Oxford University spin-out company OxDX has raised £2.6m in pre-seed funding for the development of artificial intelligence (AI)-powered rapid diagnostic technology.

Ahren Innovation Capital and IQ Capital co-led the initial funding, which also saw participation from Science Creates Ventures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OxDX intends to use the funds to expand its team and work with development partners to further validate the technology.

The company’s rapid diagnostic technology can detect and recognise specific species and strains of bacteria, viruses and other pathogens in a sample.

It combines new universal labelling technology and machine learning analysis in a neural network to identify the specific pathogens that cause infection in only a few seconds.

The company stated that the technology aims to improve the cost, speed and accuracy of infectious disease diagnosis.

OxDX CEO Alex Batchelor said: “Our ability to take a sample from someone with an unknown infection and answer the open question ‘what do they have?’ within a minute is a gamechanger for infection diagnosis and treatment.

“We’ll start with respiratory viruses and expand from there. In parallel, we’ll be simplifying the workflow to move the test from the lab to point of care, which will represent a step-change in the availability and cost of infectious disease diagnostics worldwide.”

The company has said that the technology can detect respiratory viruses in clinical samples, as well as directly identify the strain in the case of Covid-19 and influenza viruses.

OxDX aims to develop a new analysis platform that can quickly scale many diseases through software updates.